| PUBLICATION DETAILS |
Publication Date
April 2004
|
I.S.B.N. (print)
0-476-00575-2 |
I.S.B.N. (electronic)
0-476-00576-0 |
|
|
|
| DEVELOPED BY |
New Zealand Guidelines Group (NZGG)
Level 10, Cigna House
40 Mercer Street
PO Box 10 665
Wellington
NEW ZEALAND
Phone: +64 4 471 4180
Fax: +64 4 471 4185
E-mail: info@nzgg.org.nz |
|
|
|
| ENDORSED BY |
|
| REQUIRED TOOLS |
Documents are in PDF format. You'll need the FREE Adobe Acrobat Reader to browse and print them.
|
|
|
 |
 |
| Hormone Replacement Therapy |
Results from the estrogen-only arm (conjugated equine estrogen) of the Women's Health Initiative (WHI) study have just reported the following results that provide important new information for the new update of the HRT Guideline:1
- Use of ERT increases the risk of stroke. In postmenopausal women aged 50 to 79 years, the estimated absolute risk of stroke is 32 cases per 10,000 women per year in non-users of ERT compared to 44 cases per 10,000 women per year in users of ERT (averaged over 5 ½ years).
- Use of ERT decreases the risk of hip fracture. In postmenopausal women aged 50 to 79 years, the estimated absolute risk of hip fracture is 17 per 10,000 women per year in non-users of ERT compared to 11 per 10,000 women per year in users of ERT.
- There is no evidence of an increased or decreased risk of coronary heart disease in ERT users compared to non-users.
- A possible (non significant) reduction in breast cancer risk in ERT users needs further investigation.
Reference:
- The WHI Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004; 291 (14): 1701-1712
See below to download the updated guideline summary |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
We encourage readers to use this area to submit comments about the guidelines and to draw our attention to errors that inevitably will have been made in a project of this scope. |
|
|
|
|
|
|
|
|
|
|
|
